Skip to main content

Table 4 Survival estimates according to medical therapies and nephrectomy status

From: Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status—results from a Finnish nation-wide population-based study from 2005 to 2010

 

Medical treatment

    

p value

Nephrectomy status

 

No nephrectomy

(n)

Cytoreductive nephrectomy

(n)

Curative intent

(n)

Overall

(n)

 
  

Median OS, months (95% CI)

(n)

 
 

Interferon, no TT

9.5 (7.9–11.1) (41)

11.7 (5.1–18.3) (51)

17.8 (2.1–33.5) (7)

10.4 (8.1–12.7) (99)

0.043

 

TT ± interferon

10.8 (8.4–13.3) (78)

25.1 (20.4–29.8) (253)

58.7 (47.3–70.2) (34)

21.3 (17.9–24.6) (373)

< 0.001

p value

 

0.15

0.004

0.296

< 0.001

 
  1. Note: OS = overall survival, CI = confidence intervals, TT = targeted therapy